{{chembox
| Verifiedfields = changed
| verifiedrevid = 470637341
|ImageFile=Zinterol.png
|ImageSize=150px
|IUPACName=''N''-[5-[2-[(1,1-dimethyl-2-phenylethyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide
|OtherNames=
|Section1={{Chembox Identifiers
| IUPHAR_ligand = 3466
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 34825
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1243407
| InChI = 1/C19H26N2O4S/c1-19(2,12-14-7-5-4-6-8-14)20-13-18(23)15-9-10-17(22)16(11-15)21-26(3,24)25/h4-11,18,20-23H,12-13H2,1-3H3
| InChIKey = XJBCFFLVLOPYBV-UHFFFAOYAI
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H26N2O4S/c1-19(2,12-14-7-5-4-6-8-14)20-13-18(23)15-9-10-17(22)16(11-15)21-26(3,24)25/h4-11,18,20-23H,12-13H2,1-3H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XJBCFFLVLOPYBV-UHFFFAOYSA-N
| CASNo_Ref = {{cascite|changed|??}}
| CASNo=37000-20-7
| PubChem=37990
| SMILES = O=S(=O)(Nc1cc(ccc1O)C(O)CNC(C)(C)Cc2ccccc2)C
| MeSHName=Zinterol
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7167N7AJJR

  }}
|Section2={{Chembox Properties
| Formula=C<sub>19</sub>H<sub>26</sub>N<sub>2</sub>O<sub>4</sub>S
| MolarMass=378.49 g/mol
| Appearance=
| Density=
| MeltingPt=
| BoilingPt=
| Solubility=
  }}
|Section3={{Chembox Hazards
| MainHazards=
| FlashPt=
| AutoignitionPt=
  }}
}}

'''Zinterol''' is a [[beta-adrenergic agonist]].<ref name="pmid11325796">{{cite journal  |vauthors=Heubach JF, Graf EM, Molenaar P, etal |title=Murine ventricular L-type Ca2+ current is enhanced by zinterol via β1-adrenoceptors, and is reduced in TG4 mice overexpressing the human β2-adrenoceptor |journal=Br. J. Pharmacol. |volume=133 |issue=1 |pages=73–82 |date=May 2001 |pmid=11325796 |pmc=1572761 |doi=10.1038/sj.bjp.0704045}}</ref> 

Its structure is based on [[soterenol]] ([[antiarrhythmic]]) and phentermine.

==References==
{{reflist}}

{{Adrenergic agonists}}

[[Category:Sulfonamides]]
[[Category:Phenols]]
[[Category:Alcohols]]


{{pharma-stub}}